Business Update27 March 2026 at 12:44 pm
Eris Lifesciences Ltd Announces Trading Window Closure for Designated Persons
AI Summary
Eris Lifesciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. The closure will be in effect from April 01, 2026, and will remain in force until 48 hours after the declaration of the audited financial results for the quarter and financial year ending on March 31, 2026. This decision is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company.
Key Highlights
- Eris Lifesciences Ltd announces trading window closure for designated persons and their immediate relatives.
- The closure will be in effect from April 01, 2026, and will last until 48 hours after the declaration of audited financial results for the quarter and financial year ending on March 31, 2026.
- This decision is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.
- Designated persons and their immediate relatives are advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window.
- This notice operates independently and does not intend to amend, alter, modify, curtail, or extend any other notice(s) on the closure of trading window.
ERISPharmaceuticals
Eris Lifesciences LtdPrice Impact